Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) finished Wednesday with an addition of $1.52 to close at $29.01, an upside of 5.53 percent. An average of 1,269,960 shares of common stock have been traded in the last five days. There was a fall of -$3.96 in the past week, and it reached a new high 3 times over the past 12 months. The last 20 days have seen an average of 941,470 shares traded, while the 50-day average volume stands at 940,590.
ARWR stock has decreased by -15.40% in the last month. The company shares reached their 1-month lowest point of $26.93 on 08/08/23. With the stock rallying to its 52-week high on 05/05/23, shares of the company touched a low of $23.09 and a high of $48.48 in 52 weeks. It has reached a new high 2 times so far this year and lost -28.48% or -$11.55 in price. In spite of this, the price is down -40.16% from the 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Insider Transactions
ARWR stock investors should be aware that Arrowhead Pharmaceuticals Inc. (ARWR) stock had its last reported insider trading activity 38 days ago on Jul 03. In this transaction, the insider spent $315,142. Chief Discovery/Trans Medicine, Hamilton James C, disposed of 3,000 shares at a price of $35.53 on Jun 30. The insider now owns more than $106,590 worth of shares. Prior to that, Chief Financial Officer Myszkowski Kenneth Allen went on to Sale 15,000 shares at $36.20 each on Jun 27. An amount of $543,000 was transacted.
Valuation Metrics
Arrowhead Pharmaceuticals Inc. (ARWR) stock’s beta is 1.00. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 11.61, the price-to-book (PB) ratio at 6.94.
Financial Health
The quick ratio of Arrowhead Pharmaceuticals Inc. for the three months ended June 29 was 6.60, and the current ratio was 6.60, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.00 and a total debt to equity ratio of 0.00 for the quarter ending June 29. Its gross profit as reported stood at $421.74 million compared to revenue of $243.23 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Arrowhead Pharmaceuticals Inc.’s return on assets was -18.60%.
Earnings Surprise
For the three-month period that ended June 29, Arrowhead Pharmaceuticals Inc. had $346.37 million in cash. In the quarter under review, the net income was down than the previous quarter. The company posted a net income of -$102.95 million in the quarter, while revenues of $48.68 million were grew 30.01%. The analyst consensus anticipated Arrowhead Pharmaceuticals Inc.’s latest quarter earnings to come in at -$0.65 per share, but it turned out to be -$0.96, a -47.70% surprise. For the quarter, EBITDA amounted to -$100.38 million. Shareholders own equity worth $107.19 million.
Technical Picture
From a technical analysis perspective, let’s take a brief look at Arrowhead Pharmaceuticals Inc. (ARWR) price momentum. RSI 9-day as of the close on 09 August was 27.87%, suggesting the stock is oversold, with historical volatility in this time frame at 60.20%.
As of today, ARWR’s price is $30.26 -12.01% or -$3.96 from its 5-day moving average. ARWR is currently trading -14.48% lower than its 20-day SMA and +18.70% higher than its 100-day SMA. However, the stock’s current price level is -13.66% below the SMA50 and -11.04% below the SMA200.
The stochastic %K and %D were 9.85% and 5.27%, respectively, and the average true range (ATR) was 1.48. With the 14-day stochastic at 21.89% and the average true range at 1.37, the RSI (14) stands at 30.66%. The stock has reached -2.85 on the 9-day MACD Oscillator while the 14-day reading was at -4.13.
Analyst Ratings
TD Cowen launched coverage on Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) in its analyst report released on July 21, 2023. The firm assigned the stock an Outperform rating. The consensus rating for Arrowhead Pharmaceuticals Inc. (ARWR) among analysts is Overweight. According to current brokerage recommendations, 0 brokerage firms advise that investors sell ARWR, while 3 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 1 analysts, while 9 others rate it as a “buy”.
What is ARWR’s price target for the next 12 months?
Analysts predict a range of price targets between $27.00 and $90.00, with a median target of $60.00. Taking a look at these predictions, the average price target given by analysts for Arrowhead Pharmaceuticals Inc. (ARWR) stock is $59.69.
